in the first year, there is a significant risk of death based on initial presentation, as well as underlying comorbidities. To improve long-term survival, aggressive medical management and medical surveillance is warranted.
Objectives: The goal of this study was to compare outcomes of endovascular aneurysm repair (EVAR) with contemporary volume-dependent sac embolization with fibrin glue and coils (Embo-EVAR), vs endovascular aneurysm sealing system (EVAS) with the Nellix device (Endologix Inc, Irvine, Calif) in the prevention of type II endoleaks (ELII) and their complications.
Methods: This retrospective study included patients with abdominal aortic aneurysm elected for EVAR and identified as "at risk" for ELII in two vascular centers between 2014 and 2016. The definition "at risk" for ELII was patency of inferior mesenteric artery (IMA) with >3 mm diameter; patency of at least three pairs of lumbar arteries, or two pairs of lumbar arteries plus sacral artery or accessory renal artery or any diameter patent IMA. EVAS was performed according to device instructions for use. Overall, 130 patients underwent endovascular repair (Embo-EVAR, n ¼ 75 [57.7%]; EVAS, n ¼ 55 [42.3%] ). ELII rates during follow-up were compared. Freedom from any reintervention and freedom from ELII-related reintervention were compared using Kaplan-Meier estimates.
Results: Patient characteristics and Society for Vascular Surgery comorbidity scores (0.93 6 0.53 vs 0.93 6 0.52; P ¼ 1.00) as also mean aneurysm sac diameter (61 6 13 vs 57 6 8 mm; P ¼ .05) and mean sac patent lumen diameter (43 6 10 vs 45 6 9 mm; P ¼ .24) were similar between Embo-EVAR and EVAS. However, Embo-EVAR had a significantly higher number of cases with aneurysm sac patent lumen diameter >60 mm compared to EVAS (8% vs 0%; P ¼ .03). Operative time (151 6 37 vs 115 6 23 minutes; P < .001) and length of hospitalization (4.0 6 4.6 vs 2.9 6 1.8 days; P ¼ .02) were longer in Embo-EVAR compared to EVAS. Freedom from ELII was lower in Embo-EVAR at 3 months (92% vs 100%; P ¼ .04), but was similar between Embo-EVAR and EVAS at 6 (93% vs 98%; P ¼ .40), 12 (90% vs 98%; P ¼ .27), and 24 months (100% vs 100%; P ¼ 1.00). At 24 months freedom from any reintervention (Embo-EVAR, 98% vs EVAS; 95%; P ¼ .19) and freedom from ELII-related reintervention were similar (100% for both groups; P ¼ 1.00). Within Embo-EVAR, ELII-related reintervention was 0% both for patients with <60 mm and >60 mm sac patent lumen (P ¼ .1).
Conclusions: EVAS compared to Embo-EVAR is associated to shorter operative time and length of hospitalization. Although further confirmatory studies are needed, both Embo-EVAR and EVAS seem to be associated to a low rate of ELII and EIIerelated reintervention over the midterm follow-up. Embo-EVAR may be a valid alternative for prevention of EII-complications, also for large aneurysm with a sac patent lumen diameter > 60 mm. Objectives: Over the past decade, a number of endovascular approaches have evolved to treat aortic aneurysms with anatomy that is not amenable to traditional endovascular repair. Many surgeons are unsure of whether to invest the time in learning new techniques that may be of limited benefit to them in practice. The Zenith Fenestrated (Z-Fen) endograft (Cook Medical, Bloomington, Ind) represents the first commercially available product in the United States for fenestrated aortic repair. Given the novelty of this technology and the training required to use, there is uncertainty about the most appropriate settings for use. We aim to quantify practice patterns in Z-Fen use during the first 5 years of commercial availability, and we identify predictors of high and low uptake.
Methods: Complete order records for Z-Fen endografts between June 2012 and November 2016 were obtained from the device manufacture. We performed descriptive analysis of practice patterns as well as univariate and multivariate regressions of predictors of annual Z-Fen volume, including academic vs community status, number of Z-Fen-trained surgeons per site, early adoption, and proximity to other Z-Fen sites.
Results: A total of 750 surgeons have been trained to use Z-Fen, and 4133 cases have been performed at 447 centers since 2012 since Food and Drug Administration approval. Z-Fen centers were spread across the country but had a greater density in the Eastern states (Fig 1) . The average annual number of cases per trained surgeon is 4.46; however, many surgeons performed zero or very few cases following training. In the first year of training, academic programs performed an average of 3.38 cases (95% confidence interval, 2.88-.88) whereas community programs performed an average of 2.29 cases (95% confidence interval, 2.07-2.51). Over time, these annual averages diverged (Fig 2) : while there was no statistically significant increase in the annual case volume over time for community centers, academic centers increased their annual volume after training. In a multivariate stepwise regression, predictors of high annual use in the years following training included: academic center (adjusted odds ratio, 1.77; P ¼ .001) and training within the first 2 years of availability (adjusted odds ratio, 3.834; P < .001). The number of surgeons at a given center and the number of local centers were not associated with annual volume.
Conclusions: While the opportunities for Z-Fen training were available equally to academic centers and community center and while more community centers became trained, uptake of Z-Fen has proven the greatest at early-adopting academic centers, where annual volumes have been steadily increasing.
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Comparison and Short-term Outcomes in Patients Undergoing Axillobifemoral and Axillounifemoral Bypass Graft
Goran Tesic, Chenee Arthelma Tyson, Saqib Zia, Jonathan Schor, Jonathan Deitch, Kuldeep Singh. Staten Island University Hospital, New York, NY Objectives: Axillofemoral bypass is traditionally used as an alternative for aortoiliac occlusive disease. Typically axillobifemoral bypass (ABFB) is used as the procedure of choice; however, a comparison of axillounifemoral (AUFB) and ABFB is not well studied.
Methods: We queried the National Surgical Quality Improvement Program database for all patients that underwent AUFB (Current Procedural Terminology 35521) and ABFB bypass (Current Procedural Terminology 35654) performed between 2005 and 2011. We reviewed demographics, comorbidities, and 30-day outcomes. We excluded all emergency cases and all cases performed with a venous conduit. Patient demographics, comorbidities, smoking, graft failures, blood transfusions, steroid use, wound infections, failure to wean, and myocardial infarction were compared between groups using c 2 and t-test as appropriate.
Results: There were 595 patients who underwent ABFB and 96 patients in the AUFB group. Patients in AUFB group were a mean age of 68 vs 66 in the ABFB group. There were 60 male patients (62.5%) and 36 female patients (27.5%) recorded in the AUFB group, and 283 male (47.5%) and 312 female patients (52.5%) comprised the ABFB group. Primary outcomes examined were 30-day graft failure and wound infection. There was a significant difference (P ¼ .01) in short-term graft failure comparing ABFB (2.6%) and AUFB (9.1%). A significant difference (P ¼ .03) was also found when comparing the two groups in terms of wound infection occurrences within 30 days, ABFB (33.1%) and AUFB (55%). We also assessed risk factors and perioperative occurrences such as smoking (ABFB 54% vs AUFB 34%; P < .05), diabetes (ABFB 25% vs AUFB 29%; P ¼ .38), blood transfusion (AUFB 0% vs ABFB 2.2%; P ¼ .23), failure to wean from ventilation (AUFB 3.1% vs 8.4%; P ¼ .09), myocardial infarction (AUFB 2.1% vs ABFB 2.7%; P ¼ 1.0), acute renal failure (AUFB 1% vs ABFB 0.2%; P ¼ .26), and steroid use (AUFB 5.2% vs ABFB 3.9%; P ¼ .57).
Conclusions: We noted a significant difference between AUFB and ABFB short-term outcomes with regards to graft failure and wound infection. Results are favoring ABFB, despite increased complexity of the procedure and additional incisions that would favor risk of wound infection. Further studies are needed to elucidate causality and dynamics which apply.
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Visceral Objectives: Fenestrated endovascular aneurysm repair (FEVAR) is an alternative to treat complex abdominal aortic aneurysms that involve at least one of the visceral vessels. Patency of visceral vessels remains >90% when covered stents are used. The use of distal uncovered stents to prevent kinking has been reported to be an independent predictor of loss of branch patency. The aim of this study was to evaluate branch related outcomes of FEVAR using covered stents only vs the use covered and distal uncovered stents.
Methods: During a 4-year period, 139 patients (115 men [83%], and 24 women [17%]) underwent FEVAR using Zenith Fenestrated AAA Endovascular Grafts (57%), Zenith P-Branch (4%), and fenestrated premanufactured custom-made devices (39%). Patients with suprarenal, juxtarenal, and type IV thoracoabdominal aneurysms were included. Patients treated with side branched devices were excluded. Covered iCAST stents were used as bringing stents in all cases. Uncovered stents were used distally to the covered stents in 33 patients (24%). Primary end points were primary patency, defined as the absence of occlusion that required intervention. Secondary outcomes were technical success, branchrelated reinterventions, and mortality.
Results: Median age was 72 years (interquartile [IQR] , 67-78 years) for the entire cohort with a median aneurysm size of 56 mm (IQR, (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) . The median number of fenestrations was 3 (IQR, 3-4). In total, 442 target vessels were provided with 49 scallops and 393 fenestrations. Uncovered stents were used in 36 visceral vessels. Median follow-up time was 8 months (IQR, 1.5-13 months). Technical success was obtained in 440 arteries (99%). Overall, visceral vessel primary patency was 90% at 12 months and 75% at 24 months. The overall primary patency rate was 95% at 12 months and 70% at 24 months in the covered/uncovered stent group vs 91% at 12 months and 75% at 24 months when only covered stents were used (P ¼ . 9). Similarly, the rate of branch related reinterventions rate at 24 months was 15% for both groups (P ¼ .8). Patient mortality rate at 24 months was 15% for the covered/uncovered stents group vs 12% for the only covered stents group (P ¼ .3).
Conclusions: The use of distal uncovered stents to prevent kinks was not associated to decreased early branch patency. The long-term outcomes of distal uncovered stents remain to be determined. For now, the use of uncovered stents distal to covered stents may be considered to prevent kinks in complex branch anatomy.
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